PD-1/PDCD1 Human Protein Biotinylated

Product Description

PD-1/PDCD1 Human Protein Biotinylated
Catalog number: B2012555
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 10 ug
Molecular Weight or Concentration: 19.7 kDa
Supplied as: Solution
Applications: molecular tool for various biochemical applications
Storage: -20°C
Keywords: PDCD1, PD1, CD279, SLEB2, hPD-1, hPD-l, Biotinylated PD-1/PDCD1, Human Recombinant
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Zamani MR, Asbagh FA, Massoud AH, Salmaninejad A, Massoud A, Rezaei N. Association between a PD-1 gene polymorphism and antisperm antibody-related infertility in Iranian men J Assist Reprod Genet. 2015 Jan;32(1):103-6.
2: Hobo W, Hutten TJA, Schaap NPM, Dolstra H. Immune checkpoint molecules in acute myeloid leukaemia: managing the double-edged sword Br J Haematol. 2018 Apr;181(1):38-53.
3: Peters I, Tezval H, Kramer MW, Wolters M, Grünwald V, Kuczyk MA, Serth J. [Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures] Aktuelle Urol. 2015 Nov;46(6):481-5.
4: Inaguma S, Lasota J, Wang Z, Czapiewski P, Langfort R, Rys J, Szpor J, Waloszczyk P, Okoń K, Biernat W, Ikeda H, Schrump DS, Hassan R, Miettinen M. Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma Hum Pathol. 2018 Jan;71:1-7.
5: Ebrahimnezhad S, Jazayeri M, Hassanian SM, Avan A. Current Status and Prospective Regarding the Therapeutic Potential of Natural Autoantibodies in Cancer Therapy J Cell Physiol. 2017 Oct;232(10):2649-2652.
6: Kasamatsu T, Ino R, Takahashi N, Gotoh N, Minato Y, Takizawa M, Yokohama A, Handa H, Saitoh T, Tsukamoto N, Murakami H. PDCD1 and CTLA4 polymorphisms affect the susceptibility to, and clinical features of, chronic immune thrombocytopenia Br J Haematol. 2018 Mar;180(5):705-714.
7: Ribrag V, Avigan DE, Green DJ, Wise-Draper T, Posada JG, Vij R, Zhu Y, Farooqui MZH, Marinello P, Siegel DS. Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013 Br J Haematol. 2019 Aug;186(3):e41-e44.
8: Tanaka A, Zhou Y, Ogawa M, Shia J, Klimstra DS, Wang JY, Roehrl MH. STAT1 as a potential prognosis marker for poor outcomes of early stage colorectal cancer with microsatellite instability PLoS One. 2020 Apr 10;15(4):e0229252.
9: Goéré D, Flament C, Rusakiewicz S, Poirier-Colame V, Kepp O, Martins I, Pesquet J, Eggermont A, Elias D, Chaput N, Zitvogel L. Potent immunomodulatory effects of the trifunctional antibody catumaxomab Cancer Res. 2013 Aug 1;73(15):4663-73.
10: Blaker YN, Spetalen S, Brodtkorb M, Lingjaerde OC, Beiske K, Østenstad B, Sander B, Wahlin BE, Melen CM, Myklebust JH, Holte H, Delabie J, Smeland EB. The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era Br J Haematol. 2016 Oct;175(1):102-14.

Products Related to PD-1/PDCD1 Human Protein Biotinylated can be found at Conjugates